ASP Isotopes (ASPI) has restarted the first 18 stages of its Silicon-28 enrichment facility in Pretoria, South Africa, after engineering upgrades that are expected to support safer and more efficient commercial-scale production.

The restarted Silicon-28 facility news lands after a sharp 30 day share price return of 55.36% and a 90 day share price return of 43.60%, while the 1 year total shareholder return declined 9.02% and the 3 year total shareholder return is very large. This suggests momentum has recently picked up even against a mixed longer term picture.

If you are curious about other ways to get exposure to quantum and semiconductor related themes, this is a good moment to scan 29 quantum computing stocks

With ASP Isotopes still loss making but growing revenue and the stock up strongly in recent months, the key question is whether the current US$7.97 price already reflects its Silicon-28 potential, or if the recent momentum leaves room for a buying opportunity that markets have not fully priced in yet.

Price-to-Sales of 37.3x: Is It Justified?

On a simple sales based lens, ASP Isotopes appears expensive at a P/S of 37.3x compared with both its industry and closer peers, even after the recent share price pullback over the past year.

The P/S ratio compares the company’s market value with its annual revenue and is often used when companies are still loss making, as is the case here. For ASP Isotopes, the current market valuation sits far above the revenue base of $26.93m. This means investors are paying a high price today for each dollar of current sales.

Compared with the US Chemicals industry average P/S of 1.1x and a peer average of 2x, ASP Isotopes’ 37.3x multiple is far higher and indicates that the market is already factoring in strong future revenue expansion. The estimated fair P/S ratio of 6.6x is also well below the current level, highlighting a valuation point the stock could potentially trend toward if expectations and reality move closer together.

Result: Price-to-Sales of 37.3x (OVERVALUED)

However, ASP Isotopes is still reporting a net loss of US$193.11m and carries a high P/S multiple, so any setback in commercial uptake or isotope development progress could quickly pressure sentiment.

Next Steps

Weighing up the upbeat Silicon-28 progress against the current valuation and past losses, it makes sense to move quickly and test the numbers yourself so you are not relying solely on sentiment. To help with that, take a closer look at the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

ASP Isotopes might be on your radar now, but you do not want to miss other stocks that fit clear, actionable themes tailored to different investing styles.

• Target potential mispricing by scanning 45 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect their underlying business strength.
• Build a steadier income stream by reviewing 10 dividend fortresses that pair higher yields with a focus on resilience.
• Spot fresh opportunities early by checking the screener containing 22 high quality undiscovered gems that many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.